FilingSEC EDGAR8-K
MetaVia Announces Preclinical Tissue Distribution Results for DA-1726
· SEC accepted
StagePreclinical
Filing content
The company announced preclinical study results showing that DA-1726 preferentially distributes to adipose tissue and exhibits prolonged retention, supporting its once-weekly dosing profile.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…